Q1 2022 report and presentation

Tromsø, Norway, 28th April 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 49.2 million (40.9) and an EBITDA of NOK 27.9 million (25.8) for the first quarter of 2022. Highlights from Q1 2022 ArcticZymes Technologies (AZT) had Q1 sales of NOK 49.2 million growing by 21% (Q1 2021: NOK 40.9 million) Positive EBITDA of NOK 27.9 million (Q1 …

ArcticZymes Technologies attending 32nd ECCMID

ArcticZymes Technologies will attend the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place from the 23rd to 26th of April in Lisbon, Portugal. Our team is looking forward to meeting you at booth 2-11.1 located in Pavilion 3 to discuss your needs and share the latest development on our enzymes!

ArcticZymes is attending France Bioproduction Congress 6th Edition

ArcticZymes Technologies is participating at the France Bioproduction Congress 6 edition in Paris-Saclay from the 7th to 8th of April. Dr. Laurent Spenle is looking forward to meeting you at booth 8 for a discussion in how our Salt Active Nucleases can improve the efficiency of your bioproduction process.

ArcticZymes Technologies establishes a New Application Development Laboratory

Tromsø, Norway, 9th March 2022 – ArcticZymes Technologies ASA (OSE: AZT) announces the establishment of a new application development laboratory at ShareLab in Oslo. ArcticZymes Technologies has signed an agreement with ShareLab AS to lease laboratory facilities at its premises in the Oslo Science Park. These facilities will support application development activities to demonstrate the utility of the Company´s enzymes …